source
- Spyre shares plunge as rheumatoid arthritis trial of SPY072 falls short of internal targetSpyre Therapeutics reported that its antibody SPY072 did not meet the company’s internal criteria in a mid‑stage rheumatoid arthritis trial, despite showing some activity. The placebo‑controlled s…
- Biohaven secures up to $795 million partnership with SK Biopharma for global epilepsy drug rightsBiohaven announced a commercial partnership for its late-stage epilepsy program. South Korea-based SK Biopharma has agreed to pay up to $795 million for worldwide rights to the company's Kv7 ion ch…